Researchers looked at cases from 1990-2010 in which the FDA added warnings to labels, issued public health advisories or wrote letters to physicians and other prescribers to inform them of new drug risks. However, these actions did not achieve their aim or resulted in unintended consequences. For example, the FDA recommended patients taking atypical antipsychotics be tested for diabetes, but the rate of glucose testing did not increase.
Related Articles on the FDA:
Stanford Partners with FDA to Improve Medical Device Approval Process
FDA, Life Sciences Trade Group Partner to Improve Medical Device Review
FDA Clears Curos Disinfecting Port Protector
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
